Construction and functional verification of size-reduced plasmids based on TMP resistance gene dfrB10

Microbiol Spectr. 2023 Dec 12;11(6):e0120623. doi: 10.1128/spectrum.01206-23. Epub 2023 Oct 31.

Abstract

Plasmid size is one of the factors affecting transfection efficacy in most of the molecular genetic research studies. One effective approach for reducing plasmid size is to replace relatively large, conventional antibiotic resistance genes with the short-size dfrB10 gene. The successful construct of a series of dfrB10-based tool plasmids and their functional validation, via comparison with original plasmids, suggest that dfrB10 is a potent drug resistance selection marker. The antibiotic trimethoprim offers convenient usage comparable to that of ampicillin or kanamycin. Additionally, fluorescence analysis has demonstrated the compatibility of TMP with protein expression in various host cells. Based on these findings, TMP-dfrB10 could be an alternative choice for future use in molecular genetic research studies that require miniature plasmids to achieve optimal results.

Keywords: TMP; dfrB10; drug selection marker; plasmid; vector.

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Drug Resistance, Microbial
  • Plasmids / genetics
  • Trimethoprim*

Substances

  • Trimethoprim
  • Anti-Bacterial Agents